Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day

Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day

Company’s Chief Scientific Officer to Participate in “New Approaches to Combating Opioids” Panel

SANTA MONICA, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that Opiant’s Chief Scientific Officer, Phil Skolnick, Ph.D., D.Sc. (hon.), will participate in a panel at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day, to be held October 29-30, 2018, in Washington, D.C.  Dr. Skolnick will speak on a panel entitled: “New Approaches to Combating Opioids.”  The panel will be chaired by Kristen Herring, Ph.D., Health Scientist, BARDA Division of Chemical Biological Radiological Nuclear (CBRN) Countermeasures.

The panel will take place on Monday, October 29, 2018, at 3:30 PM ET.  The BARDA Chemical Threats program has made an amendment to the BARDA Broad Agency Announcement to seek opioid countermeasures with new mechanisms of action.  In this session, BARDA team members will bring together drug developers and stakeholders for an open discussion on critical factors and enablers.

“I look forward to participating in this panel, and addressing how our current development program for OPNT003, nasal nalmefene, represents a potential solution to both the dramatic rise in overdose deaths caused by synthetic opioids, like fentanyl, and the possible weaponization of synthetic opioids,” said Dr. Skolnick.  “We were recently granted a multi-year contract worth up to $4.6 million from BARDA that will accelerate development of OPNT003 as a medical countermeasure in the event of a chemical attack using synthetic opioids. We are excited to partner with BARDA in this endeavor.”

About BARDA Industry Day
The Biomedical Advanced Research and Development Authority, or BARDA, remains committed to engaging with our industry and government partners to fulfill our mission, saving lives and protecting Americans through the research and development of medical countermeasures against serious health security threats. The theme of BARDA Industry Day 2018 is: Driving Innovation. To learn more about BARDA Industry Day and this year’s event click here

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. The National Institute on Drug Abuse, a component of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals.  For more information please visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, whether or not we will be able to consummate the offering of common stock described herein, including due to the satisfaction of customary closing conditions and prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reason, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-KT for the transition period August 1 to December 31, 2017 and Form 10-Qs for the periods ended March 31, 2018 and June 30, 2018 filed with the Securities and Exchange Commission on March 7, 2018, May 8, 2018 and August 9, 2018, respectively, including under the caption titled "Risk Factors."  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746

Opiant logo.jpg

Source: Opiant Pharmaceuticals, Inc.